Results 1 to 10 of about 3,132 (216)
Real-World Data on Faricimab Switching in Treatment-Refractory Neovascular Age-Related Macular Degeneration [PDF]
LifeFaricimab is a newly approved bispecific antibody for neovascular age-related macular degeneration (nAMD). Our study aims to evaluate clinical outcomes of faricimab switching in patients with treatment-refractory nAMD; determine parameters that predict ...
Yu Jeat Chong +2 more
exaly +5 more sources
Sterile Intraocular Inflammation Associated With Faricimab [PDF]
JAMA OphthalmologyImportanceRandomized clinical trials are conducted to establish both drug safety and efficacy. However, evidence of adverse events associated with these drugs in the clinical practice setting can be of value at generating hypotheses regarding less common safety issues, even if causality cannot be determined.ObjectiveTo present and analyze cases of ...
Cozzi, Mariano +5 more
semanticscholar +6 more sources
Case Reports in Ophthalmology, 2023 This case report describes a 78-year-old patient who developed a tear of the retinal pigment epithelium (RPE) during faricimab (Vabysmo®) therapy. After three consecutive intravitreal aflibercept (Eylea®) injections with persistent disease activity ...
Christoph R Clemens +3 more
doaj +3 more sources
PharmaceuticsOur study aimed to assess the anatomical changes in the retina, including the assessment of the reduction of diabetic macular edema (DME) on optical coherence tomography (OCT) and the improvement of retinal microvascular parameters, defined by the reduction of nonperfusion areas on OCT angiography (OCTA) after intravitreal injections of 6 mg faricimab,
Dorota Śpiewak +4 more
doaj +6 more sources
Summary of Research: Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Results From the RHONE-X Extension Trial [PDF]
Ophthalmology and TherapyThis is a summary of the original article “Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Results From the RHONE-X Extension Trial.” RHONE-X was a phase 3, multicenter, nonrandomized, 2-year open-label extension of the YOSEMITE/RHINE clinical
Veeral S. Sheth +4 more
doaj +2 more sources
Clinical Ophthalmology, 2023 Ella H Leung, Daniel J Oh, Shannon E Alderson, Joshlynn Bracy, Mia McLeod, Litzi I Perez, Alexander Bottini, David Chin Yee, Krishna Mukkamala Georgia Retina, Atlanta, GA, USACorrespondence: Ella H Leung, 833 Campbell Hill St NW, Suite 300, Marietta, GA,
Leung EH +8 more
doaj +1 more source
Four-Year Outcomes of Faricimab in Diabetic Macular Edema in the RHONE-X Extension Trial: A Podcast [PDF]
Ophthalmology and TherapyDiabetic macula edema (DME) is a leading cause of vision loss among people with diabetes and requires long-term management strategies that balance efficacy, safety, and durability.
Veeral S. Sheth, Stela Vujosevic
doaj +2 more sources
Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE/RHINE Trials in Diabetic Macular Edema [PDF]
Ophthalmology RetinaPurpose: To compare anatomic biomarkers on spectral-domain OCT between faricimab, a dual angiopoietin-2 (Ang-2)/VEGF-A inhibitor, and aflibercept in a pooled analysis of results from the YOSEMITE/RHINE trials in diabetic macular edema (DME).
Jennifer I. Lim +15 more
semanticscholar +2 more sources
Ophthalmology SciencePurpose To compare the effect of faricimab, a dual angiopoietin-2 (Ang-2) and VEGF-A inhibitor, with aflibercept on resolution of hyperreflective foci (HRF) in patients with diabetic macular edema (DME).
U. Chakravarthy +12 more
semanticscholar +3 more sources
Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME
International Journal of Retina and VitreousManagement of vitreoretinal disorders (e.g., neovascular age-related macular degeneration [nAMD] and diabetic macular edema [DME]) have assumed the standard therapy of lifelong anti-VEGF injections with drugs like aflibercept, brolucizumab, ranibizumab ...
Fernando M. Penha +10 more
semanticscholar +2 more sources